Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Newave Pharmaceutical Inc
City of Hope Medical Center
MacroGenics
City of Hope Medical Center
City of Hope Medical Center
Stanford University
National Institutes of Health Clinical Center (CC)
University of California, Davis
Xencor, Inc.
Astellas Pharma Inc
City of Hope Medical Center
Stanford University
Aziende Chimiche Riunite Angelini Francesco S.p.A
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Fore Biotherapeutics
Barbara Ann Karmanos Cancer Institute
University of Wisconsin, Madison
National Institutes of Health Clinical Center (CC)
MedImmune LLC
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
University of Louisville
Alliance for Clinical Trials in Oncology
Morphotek
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Indiana University
Indiana University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)